CA2733918A1 - The treatment of hearing loss - Google Patents

The treatment of hearing loss Download PDF

Info

Publication number
CA2733918A1
CA2733918A1 CA2733918A CA2733918A CA2733918A1 CA 2733918 A1 CA2733918 A1 CA 2733918A1 CA 2733918 A CA2733918 A CA 2733918A CA 2733918 A CA2733918 A CA 2733918A CA 2733918 A1 CA2733918 A1 CA 2733918A1
Authority
CA
Canada
Prior art keywords
noise
receptor agonist
adenosine receptor
adenosine
exposure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2733918A
Other languages
English (en)
French (fr)
Inventor
Srdjan Vlajkovic
Peter Rowland Thorne
Gary David Housley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CA2733918A1 publication Critical patent/CA2733918A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2733918A 2008-08-11 2009-08-11 The treatment of hearing loss Abandoned CA2733918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ57046908 2008-08-11
NZ570469 2008-08-11
PCT/NZ2009/000164 WO2010019057A1 (en) 2008-08-11 2009-08-11 The treatment of hearing loss

Publications (1)

Publication Number Publication Date
CA2733918A1 true CA2733918A1 (en) 2010-02-18

Family

ID=41669060

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2733918A Abandoned CA2733918A1 (en) 2008-08-11 2009-08-11 The treatment of hearing loss

Country Status (8)

Country Link
US (1) US20110207689A1 (enExample)
EP (1) EP2328577A4 (enExample)
JP (1) JP2011530585A (enExample)
CN (1) CN102159209A (enExample)
AU (1) AU2009280369A1 (enExample)
CA (1) CA2733918A1 (enExample)
MX (1) MX2011001551A (enExample)
WO (1) WO2010019057A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279496B2 (ja) * 2015-01-08 2018-02-14 積水化成品工業株式会社 発泡粒子及び発泡成形体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248770A (en) * 1984-10-26 1993-09-28 The United States Of America, As Represented By The Department Of Health And Human Services Molecular probes for adenosine receptors
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
SE9401499D0 (sv) * 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
AU2603197A (en) * 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions

Also Published As

Publication number Publication date
JP2011530585A (ja) 2011-12-22
CN102159209A (zh) 2011-08-17
US20110207689A1 (en) 2011-08-25
EP2328577A4 (en) 2011-10-19
MX2011001551A (es) 2011-03-29
AU2009280369A1 (en) 2010-02-18
WO2010019057A1 (en) 2010-02-18
EP2328577A1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
Pourbakht et al. Ebselen attenuates cochlear damage caused by acoustic trauma
US10987333B2 (en) Methods and compositions for preventing and treating auditory dysfunctions
Shoji et al. Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss
US6649621B2 (en) Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
Yamashita et al. Post-exposure treatment attenuates noise-induced hearing loss
Takemura et al. Direct inner ear infusion of dexamethasone attenuates noise-induced trauma in guinea pig
KR101429735B1 (ko) 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 ｎｍｄａ 수용체 길항제의 용도
US20100254907A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP6994765B2 (ja) 難聴の処置のためのセトロンファミリーのカルシニューリン阻害剤
Minami et al. Creatine and tempol attenuate noise-induced hearing loss
Abaamrane et al. Long-term administration of magnesium after acoustic trauma caused by gunshot noise in guinea pigs
US20200188332A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
Manalo et al. Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing loss
Wong et al. Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss
Kempfle et al. Experimental drugs for the prevention or treatment of sensorineural hearing loss
TR201908928T4 (tr) Parkinsoniyan sendromları olan nörodejeneratif hastalıkları tedavi etmek için bümetanid.
WO2022020514A1 (en) Compositions and methods of treating age-related retinal dysfunction
Bielefeld Protection from noise-induced hearing loss with Src inhibitors
ES2521519T3 (es) Tratamiento de fenómenos fantasma
JP2008513407A (ja) 中枢神経由来の神経障害性疼痛の治療用テトロドトキシンおよびその誘導体
JP2015511242A (ja) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
CA2733918A1 (en) The treatment of hearing loss
Bielefeld et al. Protection from impulse noise-induced hearing loss with novel Src-protein tyrosine kinase inhibitors
US20210253689A1 (en) REGIMENS, COMPOSITIONS AND METHODS WITH CAPSAICIN AND TNF-alpha INHIBITOR
US20240294925A1 (en) Method of Treatment for Auditory Dysfunction

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140812